Health Canada clears Moderna Phase 1 trial for Bundibugyo Ebola vaccine mRNA-1469
MRNA•Health Canada clears Phase 1 trial
Health Canada cleared Moderna’s Phase 1 trial of mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus.
CEPI committed up to USD 50 million to support preclinical work, the Phase 1 study, and scaled manufacturing of additional doses.
